Essential Oils for Enhancing QOL in ASD

NCT ID: NCT02543203

Last Updated: 2021-04-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2018-03-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Essential oils (aromatic oils extracted from plant parts) are routinely used by the public and are available on the market. Investigators are conducting this study because it is unknown whether the essential oils formulations will be safe and effective for improving quality of life in children with Autism Spectrum Disorder (ASD) by helping them relax and sleep.

Children invited to participate in this study must be between 3-9 years of age and have been diagnosed with Autism Spectrum Disorder. Twenty eight children and their families will be enrolled in the study.

Participants will try two different fragrant oils in a double-blind randomized order. Each child will receive each treatment for 3 months, with a 1-month "washout" period in between during which no oil is used.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the study is to evaluate the use of two fragrant oil formulations to enhance quality of life by increasing relaxation and sleep quality in children with Autism Spectrum Disorder (ASD). Essential oils (aromatic oils extracted from plant parts) are routinely used by the public and are available on the market. Investigators are conducting this study because it is unknown whether the essential oils formulations will be safe and effective for helping children with ASD relax and sleep.

To participate in this study children must be between 3-9 years of age and have been diagnosed with Autism Spectrum Disorder. Approximately 40 children will be screened to enroll 28 children and their families in the study.

In a double-blind crossover study, participants will be randomized to treatment order. All participants will receive both fragrant oil blends. Those randomized will receive one fragrant oil blend for 3 months, with a 1-month "washout" period in between and then start the second fragrant oil blend in the last 3 months. The treatment orders are A/C and C/A.

Study participation will last for 7 months. There will be one screening visit (about 5 hours long, which can be split into 2 visits), two baseline visits (about 2 hours each), two endpoint visits (2 hours each) and 5 other clinic visits (each 45-60 minutes). Visits will take place at the OSU Nisonger Center and the OSU General Clinical Research Center.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder Quality of Life Sleep Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A/C - Reconnect, Then Coconut Oil Comparator

Participants randomized to treatment order A/C, received Reconnect for 3-months each day, morning and evening. After a washout period of one-month, they received the Coconut Oil Comparator morning and evening for 3-months.

AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.

PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser.

Group Type ACTIVE_COMPARATOR

Reconnect

Intervention Type BIOLOGICAL

Topical Essential Oils mixture and aromatic method

Coconut oil Comparator

Intervention Type BIOLOGICAL

Topical Essential Oils mixture and aromatic method

C/A - Coconut oil Blend, Then Reconnect

Participants randomized to treatment order C/A received the Coconut Oil Comparator for 3-months each day, morning and evening. After a washout period of one-month, they received Reconnect morning and evening for 3-months.

AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.

PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser.

Group Type SHAM_COMPARATOR

Reconnect

Intervention Type BIOLOGICAL

Topical Essential Oils mixture and aromatic method

Coconut oil Comparator

Intervention Type BIOLOGICAL

Topical Essential Oils mixture and aromatic method

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Reconnect

Topical Essential Oils mixture and aromatic method

Intervention Type BIOLOGICAL

Coconut oil Comparator

Topical Essential Oils mixture and aromatic method

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients between 3 and 9 years of age, inclusive;
* Diagnosis of Autism Spectrum Disorder (ASD) by DSM-V;
* Mean item score of \> or = 1.5 PedsQL Inventory;
* Care provider who can reliably bring subject to clinic visits and provide trustworthy ratings.

Exclusion Criteria

* Bipolar disorder by Child \& Adolescent Symptom Inventory (CASI, Gadow \& Sprafkin, 1997) and clinical interview/history, or major depression accompanied by family history of bipolar disorder;
* Children with allergies to essential oils;
* Children with seizure disorder/epilepsy;
* Significant physical illness (e.g., serious cardiovascular, liver or renal pathology);
* Medications specifically given for insomnia and exogenous melatonin, which have the potential to confound study results, within the previous 2 weeks before baseline;
* Anticipated changes of doses of medication or other medical treatments or supplements;
* Weight less than 10 kg;
* Sleep Disordered Breathing (SDB) as defined by a total score of \> or = 3 on the CSHQ SDB subscale and parent report;
* Nut allergies;
* Allergy to vanilla;
* A substantial trial of essential oil use within the past 6 months (i.e., consistent use for 6 weeks).
Minimum Eligible Age

3 Years

Maximum Eligible Age

9 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Young Living Essential Oils

UNKNOWN

Sponsor Role collaborator

Jill Hollway

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jill Hollway

Research Scientist and Assistant Professor, Research Psychiatry

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jill A Hollway, Ph.D., M.A.

Role: PRINCIPAL_INVESTIGATOR

Ohio State University, Nisonger Center UCEDD

Eugene Arnold, M.D.,M.A.

Role: PRINCIPAL_INVESTIGATOR

Ohio State University, Nisonger Center UCEDD

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ohio State University Nisonger Center

Columbus, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015H0005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cannabidiol for ASD Open Trial
NCT03900923 COMPLETED PHASE2
Cholesterol in ASD: Characterization and Treatment
NCT00965068 COMPLETED PHASE1/PHASE2